- Vera Therapeutics (VERA) -61% on mid-stage data for immunoglobulin A nephropathy candidate.
- Enovix (ENVX) -38%.
- ReShape Lifesciences (RSLS) -28%.
- 180 Life Sciences (ATNF) -17% announces publication of a review on the biological basis of Dupuytren’s disease.
- Cingulate (CING) -15% initiates Phase 3 Study of lead asset CTx-1301, designed as a true entire active-day treatment for ADHD.
- Kala Pharmaceuticals (KALA) -12%.
- Chemomab Therapeutics (CMMB) -12% reports top-line results from CM-101 Phase 2a liver fibrosis biomarker trial in NASH patients.
- Intelligent Living (ILAG) -10%.
- Gorilla Technology (GRRR) -10%.
- Baudax Bio (BXRX) -9%.
- Grom Social Enterprises (GROM) -7%.
- HTG Molecular Diagnostics (HTGM) -6%.
- Evaxion Biotech (EVAX) -6%.